Tag: ERBB2-positive breast cancer

MRI helps predict risk of local recurrence in upper rectal cancers

Cardiac magnetic resonance tissue biomarkers unlikely to identify cancer therapy-related cardiac dysfunction in patients with breast cancer

byGursharan Sohiand1 others

April 23, 2023

1. Cardiac magnetic resonance (CMR) imaging demonstrated myocardial inflammation and edema in patients with ERBB2-positive breast cancer after receiving trastuzumab. 2. ...

#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer

byTeddy Guo

July 26, 2022

Click to read this study in JAMA.

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

byTeddy Guo

April 5, 2022

Click to read this study in JAMA Oncology.

#VisualAbstract: Trastuzumab emtansine monotherapy is noninferior to standard neoadjuvant therapy for ERBB2+ breast cancer

byTeddy Guo

September 8, 2021

Click to read the study in JAMA Oncology.

#VisualAbstract: Pyrotinib plus capecitabine improves progression-free survival in HER2⁺ metastatic breast cancer

byTeddy Guo

March 10, 2021

Click to read the study in The Lancet Oncology.

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer

byTeddy Guo

February 3, 2021

Click to read the study in The Lancet Oncology.

#VisualAbstract: Margetuximab improves progression-free survival in patients with ERBB2⁺ advanced breast cancer compared to trastuzumab

byTeddy Guo

January 27, 2021

Click to read the study in JAMA Oncology.

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

byTeddy Guo

December 23, 2020

Click to read the study in JAMA Network Open

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result